-
公开(公告)号：US20180312523A1
公开(公告)日：2018-11-01
申请号：US15497414
申请日：2017-04-26
申请人： Ronald J. Biediger , Michele A. Benish , Lindsay Bonner Hardy , Vincent A. Boyd , Robert V. Market , Thomas P. Thrash , Brandon M. Young
发明人： Ronald J. Biediger , Michele A. Benish , Lindsay Bonner Hardy , Vincent A. Boyd , Robert V. Market , Thomas P. Thrash , Brandon M. Young
IPC分类号： C07D498/04 , C07D213/75 , C07D213/64 , C07D207/327 , C07C69/618 , C07D307/54 , C07D401/12 , C07D221/18 , C07D207/333 , C07C313/06 , C07D333/22 , C07D231/16 , C07D471/04 , C07D261/08 , C07D213/55 , C07D213/48 , C07D213/69 , C07C47/575 , C07C47/55 , C07D209/08 , C07D237/14
摘要： Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.
-
公开(公告)号：US20180312498A1
公开(公告)日：2018-11-01
申请号：US15497416
申请日：2017-04-26
申请人： Ronald J. Biediger , Michele A. Benish , Robert V. Market , Michael M. Savage , Brandon M. Young
发明人： Ronald J. Biediger , Michele A. Benish , Robert V. Market , Michael M. Savage , Brandon M. Young
IPC分类号： C07D417/12 , C07D213/75
CPC分类号： C07D417/12 , C07D213/75
摘要： Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5, X and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomer(s) of these compounds. In addition methods are provided for antagonizing the action of an α4-integrin to treat various pathophysiological conditions.
-
公开(公告)号：US10246451B2
公开(公告)日：2019-04-02
申请号：US15497416
申请日：2017-04-26
申请人： Ronald J. Biediger , Michele A. Benish , Robert V. Market , Michael M. Savage , Brandon M. Young
发明人： Ronald J. Biediger , Michele A. Benish , Robert V. Market , Michael M. Savage , Brandon M. Young
IPC分类号： C07D213/75 , C07D417/12 , A61K31/44
摘要： Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5, X and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomer(s) of these compounds. In addition methods are provided for antagonizing the action of an α4-integrin to treat various pathophysiological conditions.
-
公开(公告)号：US20190225602A1
公开(公告)日：2019-07-25
申请号：US16372189
申请日：2019-04-01
申请人： Ronald J. Biediger , Michele A. Benish , Robert V. Market , Michael M. Savage , Brandon M. Young
发明人： Ronald J. Biediger , Michele A. Benish , Robert V. Market , Michael M. Savage , Brandon M. Young
IPC分类号： C07D417/12 , C07D213/75 , C07D409/12
摘要： Provided herein are methods for antagonizing the action of an α4-integrin to treat various pathophysiological conditions utilizing pharmaceutical compositions of compounds or pharmaceutically acceptable salts or stereoisomer(s) thereof of formula I where R1, R2, R3, R4, R5, X and R6 are as described herein.
-
公开(公告)号：US06503914B1
公开(公告)日：2003-01-07
申请号：US09694145
申请日：2000-10-23
IPC分类号： C07D49504
CPC分类号： C07D495/04 , A61K31/519
摘要： Various thienopyrimidine-based analog compounds that selectively inhibit the Src family of tyrosine kinases. These compounds are thienopyrimidines and contain a hydrozone bridge created by heating a thienopyrimidine hydrazine with an aldehyde in ethanol at reflux. Such compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.
摘要翻译： 选择性抑制酪氨酸激酶的Src家族的各种噻吩并嘧啶类似物化合物。 这些化合物是噻吩并嘧啶并且含有通过在乙醇中回流加热噻吩并嘧啶肼与醛在乙醇中产生的氢环桥。 这些化合物可用于治疗各种疾病，包括过度增生性疾病，血液病，骨质疏松症，神经系统疾病，自身免疫性疾病，过敏性/免疫性疾病或病毒性感染。
-
公开(公告)号：US07285556B2
公开(公告)日：2007-10-23
申请号：US10399816
申请日：2001-10-23
IPC分类号： A61K31/519 , C07D495/04
CPC分类号： C07D495/04 , A61K31/519
摘要： Various thienopyrimidine-based analog compounds are able to selectively inhibit the Src family of tyrosine kinases. Compounds of the present invention, capable of such selective inhibition, are of the basic structure seen in formulae (I), (II) or (III): These compounds are useful in the treatment of a wide variety of diseases including hyperproliferative diseases, hematologic allergic/immunological diseases, or viral infections. Methods of synthesis of these compounds and their methods of inhibiting the Src family of tyrosine kinases are presented.
摘要翻译： 各种基于噻吩并嘧啶的类似物能够选择性地抑制酪氨酸激酶的Src家族。 能够进行这种选择性抑制的本发明化合物具有式（I），（II）或（III）中所见的基本结构：这些化合物可用于治疗多种疾病，包括过度增殖性疾病，血液学 过敏性/免疫性疾病或病毒感染。 提出了这些化合物的合成方法及其抑制酪氨酸激酶Src家族的方法。
-
公开(公告)号：USRE39267E1
公开(公告)日：2006-09-05
申请号：US10878140
申请日：2004-06-28
IPC分类号： C07D495/04 , A61K31/519 , A61P19/10 , A61P31/12
CPC分类号： C07D495/04 , A61K31/519
摘要： Various thienopyrimidine-based analog compounds that selectively inhibit the Src family of tyrosine kinases. These compounds are thienopyrimidines and contain a hydrozone bridge created by heating a thienopyrimidine hydrazine with an aldehyde in ethanol at reflux. Such compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.
摘要翻译： 选择性抑制酪氨酸激酶的Src家族的各种噻吩并嘧啶类似物化合物。 这些化合物是噻吩并嘧啶并且含有通过在乙醇中回流加热噻吩并嘧啶肼与醛在乙醇中产生的氢环桥。 这些化合物可用于治疗各种疾病，包括过度增生性疾病，血液病，骨质疏松症，神经系统疾病，自身免疫性疾病，过敏性/免疫性疾病或病毒性感染。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.039 秒)